Serum Prolidase and Ischemia-Modified Albumin Levels in Neural Tube Defects: A Comparative Study of Myelomeningocele, Meningocele, and Myeloschisis

25 April 2025 : Clinical Research

İrfan Zengin

^{ABDEF 1*}, Mehmet Edip Akyol

^{ABDEFG 2}, Mustafa Arslan

^{ABF 3}, Özkan Arabacı^{ADF 2}, Eyyüp Yürektürk^{ADF 4}, Eyüp Çetin

^{ADEFG 5}, Halit Demir^{ACDE 6}

DOI: 10.12659/MSM.947873

Med Sci Monit 2025; 31:e947873

Authors information Article notes Copyright and License information

Introduction Material and Methods Results Discussion Conclusions Rerefences

Related articles Order reprints Share article Share by email

View HTML version

Table 3 Comparison of measured serum prolidase activity and serum IMA levels between patient and control groups.

		Control (n=45)	NTD patients (n=45)	p value*
Prolidase activity (IU/L)	Mean±SDMedian (min.–max.)	1.07±0.041.06 (1.01–1.15)	2.21±0.062.21 (2.11–2.31)	0.001
IMA (ABSUs)	Mean±SDMedian (min.–max.)	0.22±0.010.21 (0.20–0.24)	0.40±0.010.41 (0.37–0.42)	0.001
^* Student t test. NTD – neural tube defect; IMA – ıschemia-modified albumin; IU/L – ınternational units per liter; ABSU – absorbance unit; SD – standard deviation.

Back to the Article